Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utility of Sodium Lactate Infusion During Septic Shock (ULIS-1)
NCT03528213Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Oct 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Sodium lactate in septic shock (3 arms), sponsored by CHU de Lille. Primary endpoint: Fluid balance at 48 hours. Started Oct 2019; status: completed.
02
Drugs
Sodium lactate
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03528213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528213.